Byondis
Frans Dekker has extensive experience in facility engineering, currently serving at Byondis since April 2020 and at Synthon since July 2007, where roles have included both Facility Engineer and Senior Maintenance Technician. Prior experience includes a position as Afdelingshoofd/technisch projectleider at Emtec BV / Systence BV from 2000 to 2007, overseeing technical projects. Earlier in the career, Frans Dekker worked at Atmos BV from 1978 to 2000 as Meewerkend afdelingshoofd productielijn, involved in the production and installation of fire ventilation systems, air treatment systems, as well as glass systems and skylights.
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.